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Allergic rhinitis is associated with elevated serum IgE levels. IgE response is mediated by the high-
affinity IgE receptor (FcεRI), which is polymorphic. Studies analyzing the association between 
allergic rhinitis and FcεRI variants have been conducted with controversial results. The objective of 
this study is to analyze, in 1,041 individuals, the putative clinical association of allergic rhinitis with 
common polymorphisms in FcεRI subunits genes. These SNPs included FECR1A rs2494262, rs2427837 
and rs2251746; FECR1B rs1441586, rs569108 and rs512555; FCER1G rs11587213, rs2070901 and 
rs11421. Statistically significant differences were observed for the FCER1B rs569108 and rs512555 
polymorphisms frequencies when comparing patients with allergic rhinitis without asthma and 
controls. The OR (95% CI) value for the 237Gly allele (rs569108) is equal to 0.26 (0.08–0.86, P = 0.017) 
and for the G allele (rs512555) it is equal to 0.27 (0.08–0.88, P = 0.020). These two SNPs are linked 
(D’ = 1.0, LOD = 56.05). Also observed was a statistically significant trend towards lower IgE values 
among allergic rhinitis patients with variant alleles for both SNPs. In conclusion, in patients with 
allergic rhinitis without asthma, the FCER1B rs569108 and rs512555 polymorphisms are associated with 
increased risk of developing allergic rhinitis and with lower IgE levels.
Allergic rhinitis is associated to family history of allergy1,2, thus suggesting that genetic risk factors may under-
lie the risk of developing, or the clinical presentation of, allergic rhinitis3–5. Allergic rhinitis is also associated 
to elevated serum IgE levels and increased mediator release from activated inflammatory cells. IgE cross-link 
allergens and bind the high-affinity IgE receptor (Fcε RI) on the surface of mast cells or basophils, releasing vas-
oactive mediators, such as histamine. Fcε RI on these cells is a heterotetramer of three subunits: Fcε RIα , Fcε RIβ 
y Fcε RIγ (α β γ 2) encoded by three genes designated as FCER1A, FCER1B and FCER1G, respectively6,7. Fcε RIα 
is the ligand-binding subunit, Fcε RIβ is a signal-augmenting subunit and Fcε RIγ is a signal-transducing sub-
unit8. In other cells, such as antigen-presenting cells including monocytes, dendritic cells or macrophages, 
Fcε RI is expressed in a trimeric form lacking the β -subunit9,10. It also has been reported that platelets, epidermal 
Langerhans cells or eosinophils can express the receptor on their cellular surface in a trimeric form11,12.
Although the search for genetic susceptibility factors related to allergic rhinitis is a promising field, gene 
variations related to Fcε RI as potential risk factors for allergic rhinitis have not been comprehensively analyzed, 
and the results available are in some cases contradictory5,13–17. The genes coding for all Fcε RI subunits are pol-
ymorphic. Some of these polymorphisms affect IgE levels and/or have been associated with atopic diseases18–23. 
The FCER1A gene is located on chromosome 1q23 (1:159259504-159278014)24 and it encodes a protein with two 
extracellular IgE-like domains7. The FCER1B gene is located on chromosome 11q12-13. The gene spans approx-
imately 10 kilobases (11:59855734-59863444)24, and it encodes a 244-amino acid protein with a non-canonic 
intracellular ITAM domain with an extra tyrosine. Fcε RI can be expressed without the β -chain, but when Fcε RIβ 
is present, receptor expression is higher7. The FCER1G gene is located on chromosome 1q23 (1:161185024-
161190489)24. The gene encodes an 86-amino acid protein. FCε R1γ plays an essential role in the induction of 
mast cell degranulation and survival25.
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Aiming to elucidate the putative association of common gene variants affecting the Fcε RI subunits in the 
clinical presentation and/or in risk of developing allergic rhinitis, we analyzed the association of the variants of 
FCER1A, FCER1B, FCER1G genes with several clinical phenotype parameters, including IgE levels, in a large 
group of well-phenotyped allergic rhinitis patients and control individuals; we also analyzed putative gene-gene 
interactions which, as yet, have not been explored.
Results
The SNP frequencies observed in the study group are consistent with those previously described in the 1000 
genomes public database for individuals with European descent24, and are at Hardy-Weinberg equilibrium. The 
genotype and allele frequencies for the nine SNPs analyzed in overall allergic rhinitis patients and control indi-
viduals are summarized in Table 1. No major frequency differences were observed when comparing patients and 
controls.
Patients were stratified in two subgroups according to their clinical presentation; allergic rhinitis alone and 
allergic rhinitis + asthma. Table 2 shows the FCER1 genotypes. Among patients with allergic rhinitis alone the 
frequencies for individuals carrying the minor alleles for the SNPs rs569108 and rs512555 were remarkably 
reduced among allergic rhinitis patients as compared to the control individuals. In fact, only three allergic rhini-
tis patients (representing 2% of this clinical subgroup) carried such minor alleles in heterozygosity, whereas 37 
controls (7.2%) carried such variant alleles. It is to be noted that no carriers of these variant alleles in homozy-
gosity were observed among all patients and controls (Table 1). Statistical significance was also observed in the 
test for trend for the SNPs rs569108 and rs512555 (χ 2 = 5.86, P = 0.015; χ 2 = 5.60, P = 0.018, respectively). The 
SNP rs569108 corresponds to a missense variant E237G, which is predicted as deleterious by Sorting Intolerant 
From Tolerant (SIFT)26, and predicted as possibly damaging by the Polymorphism Phenotyping v2 (PolyPhen-2) 
prediction27. The SNP rs512555 is a downstream gene variant whose functional effect is unknown; the high link-
age between these two SNPs in the present study (D’ = 1.0, LOD = 56.05) suggests that the genetic association 
observed in Table 2 might actually be related to the missense SNP rs569108. The rest of the SNPs analyzed did not 
reveal any differences either in genotypes or in allele frequencies, when patients with allergic rhinitis alone and 
control individuals were compared (Table 2). Among patients with allergic rhinitis + asthma none of the SNPs 
analyzed revealed significant differences when compared to control individuals (Table 2).
Because it has been suggested that FCER1 genotypes may modify IgE response21, we determined IgE val-
ues and analyzed their distribution according FCER1 genotypes. These findings are summarized in Table 3. A 
statistically significant trend can be observed towards lower IgE values among patients with variant alleles for 
the SNPs rs569108 and rs512555, confined to patients with allergic rhinitis alone. Among patients with allergic 
rhinitis + asthma who carried the above-mentioned variant alleles, the IgE values were lower as compared to 
non-carriers, but the difference was not statistically significant. The rest of the variant alleles were not related to 
the IgE levels.
Group
Non-mutated 
(frequency)
Heterozygous 
(frequency)
Homozygous 
(frequency)
Minor allele 
frequency
Comparison Allele frequency 
OR (95% C.I.); P; Pc
FCER1A
 rs2494262 Patients 0.266 0.476 0.258 0.496 0.93 (0.78–1.12); 0.411; 0.955
Controls 0.237 0.498 0.265 0.514
 rs2427837 Patients 0.563 0.371 0.066 0.251 0.95 (0.78–1.16); 0.814; 0.955
Controls 0.539 0.399 0.062 0.262
 rs2251746 Patients 0.553 0.379 0.068 0.257 1.00 (0.82–1.22); 0.872; 0.955
Controls 0.545 0.395 0.060 0.258
FCER1B
 rs1441586 Patients 0.279 0.501 0.220 0.471 1.03 (0.87–1.23); 0.500; 0.955
Controls 0.274 0.526 0.200 0.463
 rs569108 Patients 0.926 0.074 0.000 0.037 0.99 (0.62–1.57); 0.955; 0.955
Controls 0.925 0.075 0.000 0.037
 rs512555 Patients 0.928 0.072 0.000 0.036 0.99 (0.62–1.57); 0.936; 0.955
Controls 0.927 0.073 0.000 0.036
FCER1G
 rs11587213 Patients 0.718 0.262 0.019 0.150 0.96 (0.75–1.22); 0.898; 0.955
Controls 0.715 0.257 0.027 0.156
 rs2070901 Patients 0.526 0.384 0.089 0.282 0.94 (0.78–1.14); 0.732; 0.955
Controls 0.512 0.388 0.100 0.294
 rs11421 Patients 0.683 0.286 0.031 0.174 0.94 (0.75–1.17); 0.773; 0.955
Controls 0.679 0.274 0.047 0.184
Table 1.  FCER1 genotypes in overall allergic rhinitis patients and control individuals. P values correspond 
to stratified Chi-Square Tests. Pc correspond values adjusted for multiple comparisons according the False 
Discovery Rate (FDR) procedure. OR: odds ratio. CI: 95% confidence interval.
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Since a statistical significant association of the FCER1B variant alleles with IgE levels in patients with allergic 
rhinitis alone was detected, linear regression under the standard additive model, including in a single model all 
genotypes, gender, age, familial antecedents of allergic diseases, smoking and prick tests, was studied with regard 
to the IgE values. Only age, with lower IgE concentrations in older age, (p = 0.019) and the mutated genotypes 
corresponding to the FCER1B SNPs rs569108 and rs512555 genotypes (p = 0.005) remained significant. The rest 
of the putative genetic associations were discarded in the multiple analysis. No associations of genotypes or IgE 
levels were identified when individuals were stratified with regard to allergic rhinitis type (intermittent, persistent 
mild and persistent moderate), eosinophilia, FEV or asthma severity step.
Discussion
Allergic rhinitis, like other complex diseases, results from interplay of genetic and environmental risk factors3–5. 
The heritability factor has been calculated to be quite high, between 74–82%1 and 90%2, and several genetic var-
iants are known to be associated with allergic rhinitis risk in some populations3,28,29. However, associations have 
been described with genes which have a weak, or unknown, relation with allergic rhinitis pathogenesis, and it 
has been speculated that the putative associations could be due to hitherto unknown epigenetic mechanisms3. 
In contrast, the present study focuses on genes that are functionally related to the pathogenesis and the clinical 
presentation of this disease.
Our results show association of two SNPs in the FCER1B gene with the risk of developing allergic rhinitis: 
the nonsynonymous Glu237Gly (rs569108) and the 3′ UTR SNP (rs512555). The Glu237 allele is more common 
among allergic rhinitis alone patients than in healthy subjects. When allergic rhinitis + asthma patients were 
compared to healthy subjects, we observed no statistically significant differences in the allele frequencies or geno-
types. The FCER1B Glu237Gly variant has been studied in a Japanese population (233 patients with nasal allergy 
and 100 control subjects) showing an association between Gly 237 and nasal allergy and atopy30. Recently, a 
meta-analysis including these two polymorphisms16 has been published. Such study includes 4496 asthmatics and 
4571 controls for the E237G variant and 2005 cases and 1868 controls for rs1441586 from several populations: 
Caucasians, Africans and Asians. The results obtained suggest that the 237Gly allele might influence the risk for 
developing atopic asthma, although no significant association was observed in the total population. Regarding the 
rs1441586 SNP, a significant association with asthma risk was observed among Asians only16. Our findings do not 
support such an association with asthma, but they do support association with rhinitis. To date, no meta-analyses 
with allergic rhinitis patients have been performed. The close relationship between asthma and allergic rhinitis 
is well known. A majority of adult patients with asthma also suffer from allergic rhinitis17 and vice-versa (this 
study). However, the presence or absence of allergic rhinitis + asthma can be an important confounding factor 
Allergic rhinitis alone
Non-mutated 
(frequency)
Heterozygous 
(frequency)
Homozygous 
(frequency)
Minor allele 
frequency
Comparison with controls Allele 
frequency OR (95% C.I.); P; Pc
FCER1A
 rs2494262 0.275 0.503 0.221 0.473 0.85 (0.66–1.10); 0.529; 0.842
 rs2427837 0.564 0.403 0.034 0.235 0.87 (0.64–1.17); 0.585; 0.842
 rs2251746 0.550 0.403 0.047 0.248 0.95 (0.71–1.28); 0.655; 0.842
FCER1B
 rs1441586 0.315 0.450 0.235 0.460 0.99 (0.76–1.28); 0.209; 0.627
 rs569108 0.980 0.020 0.000 0.010 0.26 (0.08–0.86); 0.009; 0.041
 rs512555 0.980 0.020 0.000 0.010 0.27 (0.08–0.88); 0.009; 0.041
FCER1G
 rs11587213 0.725 0.262 0.013 0.144 0.91 (0.63–1.31); 0.891; 0.891
 rs2070901 0.523 0.409 0.067 0.272 0.90 (0.67–1.20); 0.614; 0.842
 rs11421 0.709 0.257 0.034 0.162 0.86 (0.61–1.22); 0.845; 0.891
Allergic rhinitis +Asthma Non-mutated (frequency)
Heterozygous 
(frequency)
Homozygous 
(frequency)
Minor allele 
frequency
Comparison with controls Allele 
frequency OR (95% C.I.); P; Pc
FCER1A
 rs2494262 0.266 0.467 0.266 0.500 0.95 (0.78–1.15); 0.416; 0.769
 rs2427837 0.569 0.350 0.081 0.256 0.97 (0.78–1.22); 0.511; 0.769
 rs2251746 0.560 0.359 0.081 0.260 1.02 (0.81–1.27); 0.598; 0.769
FCER1B
 rs1441586 0.274 0.512 0.214 0.470 1.03 (0.84–1.25); 0.579; 0.769
 rs569108 0.901 0.099 0.000 0.050 1.34 (0.83–2.17); 0.461; 0.769
 rs512555 0.904 0.096 0.000 0.048 1.33 (0.82–2.16); 0.553; 0.769
FCER1G
 rs11587213 0.716 0.266 0.018 0.151 0.96 (0.74–1.26); 0.881; 0.881
 rs2070901 0.527 0.374 0.099 0.286 0.96 (0.77–1.19); 0.762; 0.857
 rs11421 0.671 0.302 0.027 0.178 0.96 (0.75–1.24); 0.541; 0.769
Table 2.  FCER1 genotypes in patients with allergic rhinitis classified according the presence of asthma.
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in the studies carried out so far, which did not discriminate these clinical presentations. In this sense careful 
phenotyping using strictly defined guidelines should be used to elucidate whether the putative associations with 
FECR1 polymorphisms are related to asthma or to concomitant allergic rhinitis. In this sense, we cannot rule out 
that environmental factors may modify the observed associations. Further PheWas studies would be necessary 
to elucidate this point.
The functional mechanism underlying the association found in our study is a matter of speculation, and there 
are certain aspects which should be taken into consideration. The regulation of the expression of Fcε RI is crucial 
to the receptor function. It is known that both the expression of Fcε RIβ subunit and the serum levels of IgE are 
important regulating factors. Fcε RIβ regulates the receptor response to IgE through its capacity to amplifying 
receptor signaling. IgE- Fcε RI binding causes overexpression of the receptor18,20 with an increase in the total 
Fcε RIα content on the surface. This process can be reverted by the removal of IgE, which results in a reduction in 
receptor expression and Fcε RIα content19. The relation between FCER1B variants and IgE levels is controversial. 
A wide variation in the IgE levels, consistent with previous studies, was observed in the present study31,32. We 
observed that the FCER1B variants are associated with lower serum IgE levels, in a group of patients phenotyped 
to discriminate between patients with allergic rhinitis without asthma and allergic rhinitis + asthma. The asso-
ciation is lost when all allergic rhinitis patients are merged as a single clinical group, as has been done in most 
previous studies. Another source of variability with previous findings is that the variant alleles analyzed in this 
study show different frequencies in diverse ethnicities24; these differences could explain, at least in part, the dif-
ferent results described to date.
Several studies have reported an association between several FCER1A variants and total serum IgE levels21 as 
well as increased risk for atopic eczema and asthma. We failed to replicate the previously described association 
of IgE levels with the FCER1A polymorphism rs2427837, although it is important to note that this association 
was described in a specific population corresponding to a general population of individuals living in Augsburg21. 
Genotype
Allergic rhinitis 
alone
K-W Test 
across 
genotypes 
P; Pc
Allergic 
rinitis + Asthma
K-W Test 
across 
genotypes 
P; Pc Overall patients
K-W Test 
across 
genotypes 
P; Pc
FCER1A
 rs2494262 C/C 184.94 ± 232.47
P = 0.139; 
Pc = 0.250
346.51 ± 482.83
P = 0.560; 
Pc = 0.937
294.33 ± 424.13
P = 0.935; 
Pc = 0.972C/A 187.68 ± 188.84 267.86 ± 333.20 239.74 ± 293.54
A/A 266.87 ± 292.81 306.76 ± 634.82 297.62 ± 555.56
 rs2427837 G/G 194.33 ± 226.68
P = 0.343; 
Pc = 0.514
300.01 ± 412.43
P = 0.937; 
Pc = 0.937
265.68 ± 362.08
P = 0.841; 
Pc = 0.972G/A 226.68 ± 241.53 290.18 ± 558.77 267.13 ± 468.99
A/A 140.60 ± 118.43 328.59 ± 421.92 298.76 ± 384.97
 rs2251746 T/T 190.06 ± 226.53
P = 0.034; 
c = 0.102
298.66 ± 413.61
P = 0.915; 
Pc = 0.937
263.74 ± 368.07
P = 0.372; 
Pc = 0.837T/C 238.70 ± 238.76 297.09 ± 554.46 276.18 ± 466.41
C/C 105.86 ± 113.70 302.71 ± 425.47 255.75 ± 376.03
FCER1B
 rs1441586 T/T 176.95 ± 174.85
P = 0.098; 
Pc = 0.221
267.91 ± 326.28
P = 0.344; 
Pc = 0.830
233.06 ± 280.70
P = 0.972; 
Pc = 0.972T/C 236.85 ± 248.41 286.22 ± 399.42 272.75 ± 361.14
C/C 181.37 ± 252.96 374.63 ± 738.18 303.91 ± 616.37
 rs569108 A/A 210.43 ± 229.10
P = 0.006; 
Pc = 0.027
309.51 ± 487.16
P = 0.242; 
Pc = 0.830
275.40 ± 419.36
P = 0.114; 
Pc = 0.549A/G 11.00 ± 4.58 175.38 ± 165.47 160.91 ± 164.89
G/G – – –
 rs512555 C/C 210.43 ± 229.10
P = 0.006; 
Pc = 0.027
308.11 ± 485.44
P = 0.369; 
Pc = 0.830
274.67 ± 418.34
P = 0.183; 
Pc = 0.549C/T 11.00 ± 4.58 182.70 ± 166.24 166.91 ± 166.18
T/T – – –
FCER1G
 rs11587213 A/A 200.60 ± 231.02
P = 0.954; 
Pc = 0.954
310.60 ± 510.95
P = 0.737; 
Pc = 0.937
273.55 ± 440.24
P = 0.921; 
Pc = 0.972A/G 224.68 ± 229.73 257.38 ± 307.77 249.42 ± 285.10
G/G 152.00 ± 80.61 380.17 ± 666.52 323.13 ± 573.94
 rs2070901 G/G 211.39 ± 219.17
P = 0.843; 
Pc = 0.954
299.32 ± 421.34
P = 0.834; 
Pc = 0.937
271.91 ± 370.55
P = 0.969; 
Pc = 0.972G/T 187.57 ± 181.20 312.20 ± 576.70 267.26 ± 476.60
T/T 279.13 ± 489.95 247.19 ± 244.88 254.28 ± 307.33
 rs11421 T/T 201.13 ± 232.38
P = 0.918; 
Pc = 0.954
269.59 ± 464.41
P = 0.089; 
Pc = 0.801
274.04 ± 401.77
P = 0.163; 
Pc = 0.549T/C 225.03 ± 232.90 338.47 ± 464.41 305.21 ± 421.82
C/C 143.67 ± 52.71 587.43 ± 471.60 430.36 ± 426.20
Table 3.  IgE values according to FCER1 genotypes. P values correspond to Kruskal-Wallis tests for 
independent samples. Pc correspond values adjusted for multiple comparisons according the False Discovery 
Rate (FDR) procedure. K-W test: Kruskall-Wallis test.
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Another study in a Han Chinese population failed to find an association between FCER1A variants and IgE level 
or allergic allergic rhinitis susceptibility22.
Summing up, we have identified an association of FCER1B variants with the risk of developing allergic rhi-
nitis alone, and with IgE levels in these patients. Further association studies using well-phenotyped patients are 
required to identify genetic associations that, so far, may have been overlooked in studies considering heteroge-
neous groups of patients.
Methods
Study Population. We studied a cohort of 1,041 individuals, composed of 515 unrelated patients with aller-
gic rhinitis and 526 unrelated healthy controls. Written consent for participation was obtained for all participants. 
All the patients and 97% of the control subjects who were invited to participate in the study agreed to do so.
Of the patients, 265 were recruited from the Allergy Department, Infanta Cristina Hospital (Badajoz, Spain) 
and 250 were recruited from the UGC Allergy, Regional Hospital (Málaga, Spain). Clinical characteristics of the 
participants are summarized in Table 4. Most of these patients had participated in a previous study and their 
clinical characterization has been described elsewhere33. Diagnosis for allergic rhinitis was based on the diag-
nostic criteria defined by the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology34. All 
patients were diagnosed by an allergy specialist and had a positive skin prick test35 for one or more aeroallergens. 
Of the 515 patients with allergic rhinitis, 366 (71.1%) was diagnosed with allergic asthma, according to American 
Thoracic Society criteria36. These patients were classified as defined by the step classification of the Global 
Initiative for Asthma guidelines37. A total of 526 unrelated healthy controls, from the same geographic area, and 
ethnically matched with patients, were included in the study. Medical history was obtained and examination was 
performed for each participant to exclude pre-existing disorders. Individuals with familial (up to second-degree 
relatives) or personal antecedents of allergic, atopic or autoimmune diseases were excluded. Control subjects 
were selected from staff and from medical students belonging to the Hospitals and the Universities participating 
in the study.
No statistically significant differences between cases and controls were observed for gender. Age was not dif-
ferent when comparing the overall group of patients and controls (T-Test P = 0.190). However patients with aller-
gic rhinitis alone had a mean age slightly lower than controls (P = 0.035). The percentage of smokers was lower 
among patients with rhinitis plus asthma (Chi-Square test P = 0.002) as compared to control individuals, whereas 
the percentage of smokers was higher among patients with allergic rhinitis alone (P = 0.002) as compared to con-
trol individuals. The protocol for this study was in accordance with the Declaration of Helsinki and its subsequent 
revisions, and it was approved by the respective Ethics Committees of the participating Hospitals. All individuals 
were Spanish Caucasians.
Genotype analysis. Genomic DNA was obtained from leukocytes and purified according to standard pro-
cedures. The selection of the SNPs analyzed was based on allele frequencies in the study population (higher than 
0.01), as well as functional or clinical relevance, in accordance with the public 1000 genomes database24 and pub-
lished evidence38,39. SNP analyses were performed by means of TaqMan assays (Life Technologies, Alcobendas, 
Spain). Details of these assays are provided in supplemental Table S1. Detection was carried out by qPCR in a 
7500 Real Time qPCR system (Life Technologies, Alcobendas, Spain). The amplification conditions were those 
recommended for the manufacturer. All SNP analyses were carried out in triplicate.
Statistical analyses. Statistical analyses were carried out by using the Statistical Package for the Social 
Sciences (SPSS) version 19.0 for Windows (SPSS Inc., Chicago, Ill. USA). Genotype, allelic and Hardy-Weinberg 
equilibrium analyses were performed by using the software PLINK40.
The comparison of the frequencies for alleles and genotypes between patients and control individuals was 
performed with the χ 2 statistics or Fisher exact test, as appropriate. The putative association between the SNPs 
and the risk of developing rhinitis was estimated by determining the odds ratio (OR) and the 95% confidence 
interval (CI). Multiple comparison adjustments were done by using the False Discover Rate (FDR) correction41. 
Overall patients with allergic 
rhinitis (n = 515)
Patients with allergic rhinitis plus 
asthma (n = 366)
Patients with allergic 
rhinitis alone (n = 149) Healthy subjects (n = 526)
Women, n (%) 294 (57.1%) 193 (52.7%) 82 (55.0%) 265 (50.4%)
Age ± sd (range) 32.2 ± 15.1 (14–79) 30.1 ± 13.2 (14–79) 32.5 ± 16.5 (14–77) 28.4 ± 12.1 (18–84)
Smokers, n (%) 151 (29.3%) 82 (22.4%) 69 (46.3%) 168 (31.9%)
Familial antecedents, n (%) 206 (40.0%) 155 (42.3%) 51 (34.2%) 0 (0%)
Total IgE (IU/mL) ± sd (range) 254.1 ± 401.5 (0–4800) 287.2 ± 464.1 (0–4800) 205.7 ± 228.4 (4–1469) not determined
Eosinophilia, n (%) 88 (17.0%) 86 (23.4%) 2 (1.3%) not determined
Allergic rhinitis type, n (%) 116/239/160 (22.5/46.4/74.4) 62/185/119 (16.9/50.5/32.5) 54/54/41 (2) (34.2/34.2/27.5) n.a.
FEV1 (% predicted) n.a. 94 ± 62 n.a. n.a.
Asthma severity step 1,2,3,4, n (%) n.a. 106/130/107/23 (29.0/35.5/29.2/6.3) n.a. n.a.
Table 4.  Characteristics of the individuals included in the study. Eosinophilia is defined as an eosinophils 
count over 400/ml or over 6% of white cells. The category smokers includes ex-smokers. Allergic rhinitis type 
was classified as follows (intermittent, persistent mild and persistent moderate). n.a. Not applicable. FEV: 
Forced expiratory volume.
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The statistical significance of the differences in analytical or clinical parameters were calculated by using the 
non-parametric Kruskall-Wallis test for independent samples. The gene-dose effect was analyzed by using the test 
for trend (Cochran-Armitage test). Potential confounders considered in this study were the type of allergic rhi-
nitis, age, gender, familial antecedents of the disease, smoking habits, the presence of asthma and asthma severity 
step. Multiple analyses were performed by using logistic regression. Differences in the parameters determined 
were considered to be statistically significant when adjusted p values were lower than 0.05.
In order to calculate the statistical power of the study, we evaluated the sample size with a genetic model based 
on the frequency for carriers of the risk SNP with an OR value = 2 (α = 0.05). According to the sample size in this 
study, the statistical power (two-sided associations) for the risk related to the presence of the variant alleles was 
higher than 99.8% for all SNPs except for the SNPs rs569108 (power = 93.2%) and rs512555 (power = 92.6%).
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